Acebilustat

DRUG3 trials

Sponsors

Stanford University

Conditions

Covid19Lymphedema of Upper Arm

Phase 2

COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol

CompletedNCT04662086

Stanford UniversityCovid19

Start: 2021-04-23End: 2023-02-02Updated: 2023-06-28

COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Acebilustat Sub-Protocol

CompletedNCT04662060

Stanford UniversityCovid19

Start: 2021-04-23End: 2023-02-02Updated: 2023-06-13

Trial of Acebilustat for the Treatment of Upper Arm Lymphedema

Active, not recruitingNCT05203835

Stanford UniversityLymphedema of Upper Arm

Start: 2022-07-27End: 2026-03-31Target: 40Updated: 2025-11-25

Related Papers

Evaluation of Acebilustat, a Selective Inhibitor of Leukotriene B4 Biosynthesis, for Treatment of Outpatients With Mild-Moderate Coronavirus Disease 2019: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial

Clinical Infectious Diseases2023-03-304 citations